Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy

NCT: NCT07737093 · RECRUITING

NCT IDNCT07737093
StatusRECRUITING
Start Date2026-06-20
Completion2026-12-15
SponsorRiphah International University (OTHER)
First posted
Last updated

Brief Summary

Lobectomy patients frequently experience postoperative respiratory complications such as secretion retention, dyspnea, impaired gas exchange, and reduced lung function, which can delay recovery. Oscillatory Positive Expiratory Pressure (OPEP) devices such as Acapella and Flutter are commonly used to improve airway clearance and pulmonary function. This study aims to compare the effects of Acapella and Flutter devices on secretion clearance, dyspnea, arterial blood gases, and lung function in post-lobectomy patients.

Frequently Asked Questions

What is Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy?

Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy is a clinical trial registered under NCT07737093. Current status: RECRUITING.

What is the status of NCT07737093?

The current status of NCT07737093 (Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy) is: RECRUITING.

When did Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy start?

Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy started on 2026-06-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.